Parexel, one of the largest clinical research organizations (CROs) in the world, has recently appointed Gwyn Bebb, a medical oncologist with over 20 years of experience, as Senior Vice President and Global Therapeutic Area Head for Oncology. In his new role, Dr. Bebb will lead the research and development efforts for new cancer treatments for biopharmaceutical customers worldwide.
According to Amy McKee, Chief Medical Officer and Head of the Oncology Center of Excellence, the field of oncology is complex and requires agile teams to push the boundaries of drug development. Dr. Bebb’s expertise and leadership will be invaluable in delivering groundbreaking treatment options for cancer patients.
Dr. Bebb has an impressive background in both academia and the clinical research and biotechnology industries. He previously served as a Clinical Research Medical Director at Amgen, where he played a key role in the development of a T cell engager for Phase III trials. Additionally, he held a professorship at the University of Calgary, where he established the Precision Oncology Experimental Therapeutics program and directed the Clinical Trials Unit at the Tom Baker Cancer Centre. Dr. Bebb also founded a lung cancer database to study the association between patient outcomes and molecular markers
.Peyton Howell, Chief Operating and Growth Officer of Parexel, emphasized the urgent need for new cancer treatments and the company’s commitment to addressing this need. Parexel aims to expand its expertise and leadership in oncology and other therapeutic areas to better serve patients.
Dr. Bebb’s educational background is impressive, with degrees from prestigious institutions such as the University of Cambridge, the University of Oxford, and the University of British Columbia.
In conclusion, Parexel’s appointment of Gwyn Bebb as the head of oncology clinical development demonstrates the company’s dedication to advancing cancer research and delivering innovative treatments for patients. Dr. Bebb’s extensive experience and expertise make him a valuable addition to the team.
Keywords: Parexel, Gwyn Bebb, oncology clinical development, cancer treatments, clinical research organizations, biopharmaceutical customers, drug development, academic research, Precision Oncology Experimental Therapeutics, lung cancer database, patient outcomes, molecular markers.
